Carisma Therapeutics Unveils Delisting Plans from Nasdaq
Carisma Therapeutics Inc. (OTCID: CARM) recently announced that its Board of Directors has approved a pivotal decision to voluntarily delist its common stock from The Nasdaq Stock Market LLC. This strategic move is aimed at deregistering the company’s common stock to suspend and ultimately conclude its reporting obligations under the Securities and Exchange Act of 1934.
Reasons Behind Delisting
The decision follows a series of recent communications, including a delisting determination letter received from Nasdaq due to the company's failure to meet specific compliance criteria. These included standards related to bid price, market capitalization, and publicly held shares that are stipulated in Nasdaq Listing Rules.
Transition to OTC Markets
Carisma's common stock was suspended from trading on Nasdaq as of October 13, marking its transition to the OTCID market where it began trading under the symbol "CARM". This shift is a significant change in the company’s market presence as it seeks to streamline operations and focus on other business aspects.
Future Steps After Delisting
Following the voluntary delisting, Carisma plans to file a Form 25 with the SEC. This filing is crucial as it formalizes the process of removing the company's common stock from Nasdaq. The company aims to complete this delisting by filing with the SEC, with an expected effectuation date in late December.
Operational Strategies Moving Forward
With these changes, Carisma is aligning its resources to focus more efficiently on its operations. The company has expressed that the decision to deregister and delist stems from a careful assessment of its position and the ongoing wind down of operations. By minimizing its reporting obligations, Carisma aims to protect its remaining cash assets.
About Carisma Therapeutics
Carisma Therapeutics is dedicated to biotechnology, leveraging its expertise in macrophage engineering to explore innovative therapies targeting serious diseases like liver fibrosis and cancer. The company, headquartered in Philadelphia, has been a frontrunner in developing transformative treatments that could significantly impact patient care.
Contact Information
For more inquiries regarding the company's recent developments, please contact Steven Kelly via email at steven.kelly@carismatx.com.
Frequently Asked Questions
What prompted Carisma Therapeutics to delist from Nasdaq?
Carisma decided to voluntarily delist due to noncompliance with Nasdaq’s standards for bid price and market capitalization.
What does this mean for investors?
This delisting means that the stock will no longer be traded on Nasdaq, but it will continue to be available on OTC Markets under the symbol "CARM".
When will the formal delisting take effect?
The formal delisting is expected to take effect around late December, contingent upon the filing of necessary forms with the SEC.
How will Carisma manage its operations post-delisting?
The company plans to focus on an orderly wind down and preserve cash to manage expenses effectively.
What are Carisma’s core focuses moving forward?
Carisma will continue its focus on biotechnology development, especially in therapies for serious conditions like cancer and liver diseases.
